JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.
|Videos|August 3, 2017
Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Related to this article
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5